[C-11]NPA PET-amphetamine in Cocaine Use Disorders (Aim 2)

What this Trial Is About

Researchers are investigating cocaine use disorder (CUD), a chronic condition marked by frequent relapses and abstinence periods. This early phase 1 study aims to understand the brain's chemical changes related to stress and relapse by examining dopamine release after amphetamine use and its link to the nociceptin opioid peptide receptor (NOP) system, which helps counteract stress effects in the brain. The study explores how this system may fail in people with CUD, potentially leading to relapse. Participants will undergo a series of scans and drug challenges. They will first have a baseline [C-11]NPA PET scan to measure brain receptor activity, followed by oral administration of d-amphetamine at 0.5 mg/Kg to stimulate dopamine release. After 2.5 to 3 hours, a second [C-11]NPA PET scan will be performed to observe changes in dopamine activity. This imaging approach helps link brain receptor expression to dopamine release in relevant brain regions. Throughout the study, participants will be closely monitored with PET scans before and after amphetamine administration. Researchers will measure changes in dopamine receptor binding potential to evaluate brain responses. Additional eligibility requirements include medical history reviews, physical exams, and ensuring no interfering medications or conditions. The primary outcome is the change in binding potential relative to non-displaceable uptake measured at baseline and post-amphetamine, with follow-up planned over twelve weeks to relate findings to relapse risk.

[C-11]NPA PET-amphetamine in Cocaine Use Disorders